Guillain-Barre Syndrome Drug Pipeline Analysis Report 2025

Guillain-Barre syndrome (GBS) is a rare autoimmune disorder in which the body's immune system attacks the peripheral nerves, leading to muscle weakness and paralysis. It accounts for approximately 0.38 to 2.53 cases per 100,000 person-years worldwide. There is a significant unmet clinical need for improved therapies, as current treatment options, such as intravenous immunoglobulin (IVIG) and plasma exchange, have limitations. The growing emphasis on novel immunomodulatory approaches and targeted Guillain-Barre syndrome therapeutic products is expected to drive pipeline growth. Promising drug candidates, including monoclonal antibodies and complement inhibitors, are under investigation to improve patient outcomes.

Report Coverage

The Guillain-Barre Syndrome Drug Pipeline Insight Report by the publisher gives comprehensive insights into Guillain-Barre syndrome therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for Guillain-Barre syndrome. The Guillain-Barre syndrome report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The Guillain-Barre syndrome pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with Guillain-Barre syndrome treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to Guillain-Barre syndrome.

Guillain-Barre Syndrome Drug Pipeline Outlook

Guillain-Barre syndrome is a rare autoimmune disorder where the body's immune system attacks the peripheral nervous system, leading to muscle weakness, paralysis, and, in severe cases, respiratory failure. It often follows an infection, such as a respiratory or gastrointestinal illness, which triggers the immune response that damages nerve tissues.

Treatment for Guillain-Barre syndrome focuses on managing symptoms and accelerating recovery. Current therapies include intravenous immunoglobulin (IVIG) and plasma exchange, both aimed at reducing the immune response. Supportive care, such as respiratory assistance, may be necessary for severe cases, while physical therapy helps in regaining strength and mobility.

Guillain-Barre Syndrome Epidemiology

A 2024 study reports that Guillain-Barré syndrome incidence varies globally, ranging from 0.38 to 2.53 cases per 100,000 individuals annually. European and North American populations show annual incidences between 0.84 and 1.91 per 100,000, while incidences in Asian populations, such as Japan, are notably lower at 0.44 per 100,000 individuals. These epidemiological findings inform ongoing therapeutic developments for Guillain-Barré syndrome.

Guillain-Barre Syndrome Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of Guillain-Barre syndrome drug candidates based on several segmentations, including:

By Phase

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Drug Class

• Small Molecules
• Monoclonal Antibodies
• Gene Therapies
• Biologics
• Plasma-derived Therapies
• Others

By Route of Administration

• Oral
• Parenteral
• Others

Guillain-Barre Syndrome Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phases II and IV encompass a significant share of the total Guillain-Barre syndrome clinical trials.

Guillain-Barre Syndrome - Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the Guillain-Barre syndrome pipeline analysis include monoclonal antibodies, small molecules, gene therapies, biologics, plasma-derived therapies, and others. The Guillain-Barre syndrome report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for Guillain-Barre syndrome.

Guillain-Barre Syndrome Clinical Trials Therapeutic Assessment - Competitive Dynamics

The report for the Guillain-Barre syndrome drug pipeline covers the profiles of key companies involved in clinical trials and their drugs under development. It provides a detailed Guillain-Barre syndrome therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in Guillain-Barre syndrome clinical trials:

• Argenx
• Annexon, Inc.
• Hansa Biopharma AB
• Nihon Pharmaceutical Co., Ltd.
• Alexion Pharmaceuticals, Inc.
• CuraVac
• Grifols S A
• Octapharma AG

Guillain-Barre Syndrome Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for Guillain-Barre syndrome. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of Guillain-Barre syndrome drug candidates.

Drug: ANX005

The Phase III study, sponsored by Annexon, Inc., evaluates the efficacy and safety of ANX005, a first-in-class C1q blocking antibody, in Guillain-Barré syndrome (GBS). The trial met its primary endpoint, demonstrating a 2.4-fold improvement in Guillain-Barré syndrome -disability scale at week 8. ANX005 showed early and sustained benefits, including improved muscle strength, reduced nerve damage, and shorter ventilation dependency.

Drug: Efgartigimod

The Phase III clinical trial, sponsored by Chafic Karam at the University of Pennsylvania, evaluates the safety and efficacy of Efgartigimod in Guillain-Barré syndrome (GBS) patients. The study aims to determine whether Efgartigimod improves patient outcomes. The study is expected to be completed by May 2027 and will enroll around 30 participants.

Drug: Imlifidase

Hansa Biopharma’s investigational drug, Imlifidase, has shown promising results in treating Guillain-Barré syndrome (GBS). The objective of this Phase II study (15-HMedIdeS-09) was to examine the drug’s efficacy in improving motor function. Patients receiving Imlifidase with IVIg regained independent walking in 16 days, nearly six weeks faster than those treated with IVIg alone in the IGOS study.

Reasons To Buy This Report

The Guillain-Barre Syndrome Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for Guillain-Barre syndrome. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into Guillain-Barre syndrome collaborations, regulatory environments, and potential growth opportunities.

Key Questions Answered in the Guillain-Barre Syndrome - Pipeline Insight Report

• Which companies/institutions are leading the Guillain-Barre syndrome drug development?
• What is the efficacy and safety profile of Guillain-Barre syndrome pipeline drugs?
• Which company is leading the Guillain-Barre syndrome pipeline development activities?
• What is the current Guillain-Barre syndrome commercial assessment?
• What are the opportunities and challenges present in the Guillain-Barre syndrome drug pipeline landscape?
• What is the efficacy and safety profile of Guillain-Barre syndrome pipeline drugs?
• Which company is conducting major trials for Guillain-Barre syndrome drugs?
• Which companies/institutions are involved in Guillain-Barre syndrome collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in Guillain-Barre syndrome?

This product will be delivered within 3-5 business days.